ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SXTPW 60 Degrees Pharmaceuticals Inc

0.10
0.0058 (6.16%)
May 03 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,732
Bid Price 0.035
Ask Price 0.12
News -
Share Name Share Symbol Market Stock Type
60 Degrees Pharmaceuticals Inc SXTPW NASDAQ Equity Warrant
  Price Change Price Change % Share Price Last Trade
0.0058 6.16% 0.10 18:59:59
Open Price Low Price High Price Close Price Previous Close
0.11 0.0919 0.11 0.10 0.0942
Trades Shares Traded VWAP Financial Volume Average Volume
30 3,732  0.1015513  379 -
Last Trade Type Quantity Price Currency
15:00:00 100  0.10 USD

60 Degrees Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.22M 5.80M - 254k -3.77M -0.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News 60 Degrees Pharmaceuticals

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SXTPW Message Board. Create One! See More Posts on SXTPW Message Board See More Message Board Posts

SXTPW Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.

Your Recent History

Delayed Upgrade Clock